003000 — Bukwang Pharm Co Income Statement
0.000.00%
Last trade - 00:00- KR₩275bn
- KR₩224bn
- KR₩160bn
- 64
- 46
- 38
- 48
Annual income statement for Bukwang Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 169,660 | 182,491 | 190,909 | 125,928 | 160,087 |
| Cost of Revenue | |||||
| Gross Profit | 71,641 | 75,758 | 79,429 | 47,074 | 74,343 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 169,170 | 176,869 | 191,140 | 164,151 | 160,599 |
| Operating Profit | 490 | 5,622 | -231 | -38,223 | -512 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8,300 | 3,787 | -1,033 | -39,569 | -2,970 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10,105 | -2,797 | -4,249 | -34,407 | -3,459 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -7,203 | -917 | -2,475 | -31,330 | -2,641 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7,203 | -917 | -2,475 | -31,330 | -2,641 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -72 | -15.5 | -36.6 | -451 | -18.9 |
| Dividends per Share |